General Information of Drug (ID: DM32NWD)

Drug Name
LIK-066 Drug Info
Indication
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Phase 2 [1]
Type-2 diabetes 5A11 Phase 2 [2]
Cross-matching ID
PubChem CID
52913524
CAS Number
CAS 1291094-73-9
TTD Drug ID
DM32NWD
VARIDT Drug ID
DR01082

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dapagliflozin DM28UJG Non-insulin dependent diabetes 5A11 Approved [4]
Empagliflozin DMRF9YK Type-1 diabetes 5A10 Approved [4]
Canagliflozin DMFRM1I Non-insulin dependent diabetes 5A11 Approved [5]
PF-04971729 DM79VXT Type-2 diabetes 5A11 Approved [6]
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [7]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [8]
ASP1941 DMGQ1TV Liver disease DB90-BD99 Phase 3 [9]
Remogliflozin etabonate DMW4YK1 Type-1/2 diabetes 5A10-5A11 Phase 2 [10]
AVE-2268 DMA42BV Diabetic complication 5A2Y Phase 2 [11]
YM-543 DMRZBPI Type-2 diabetes 5A11 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [7]
YG1699 DM1NR1J Type-1 diabetes 5A10 Phase 2 [13]
1614235 + 2330672 DMD751X Type-2 diabetes 5A11 Phase 1 [3]
GSK1614235 DM7I1AQ Type-2 diabetes 5A11 Phase 1 [14]
LX2761 DM8ZS7T Type 2 diabetes 5A11 Phase 1 [15]
T-1095 DMGFS51 Diabetic complication 5A2Y Discontinued in Phase 2 [16]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [17]
KURARINONE DMH0G8W Discovery agent N.A. Investigative [17]
10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X Discovery agent N.A. Investigative [18]
Alstiphyllanine F DMKRAEW Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/glucose cotransporter 1 (SGLT1) TT2UE56 SC5A1_HUMAN Inhibitor [3]
Sodium/glucose cotransporter 2 (SGLT2) TTLWPVF SC5A2_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01824264) Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
7 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
12 Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.
13 ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
14 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
15 Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
16 T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
17 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
18 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.